دورية أكاديمية
MRI radiomics to monitor therapeutic outcome of sorafenib plus IHA transcatheter NK cell combination therapy in hepatocellular carcinoma.
العنوان: | MRI radiomics to monitor therapeutic outcome of sorafenib plus IHA transcatheter NK cell combination therapy in hepatocellular carcinoma. |
---|---|
المؤلفون: | Yu, Guangbo, Zhang, Zigeng, Eresen, Aydin, Hou, Qiaoming, Garcia, Emilie Elizabeth, Yu, Zeyang, Abi-Jaoudeh, Nadine, Yaghmai, Vahid, Zhang, Zhuoli |
المصدر: | J Transl Med ; ISSN:1479-5876 ; Volume:22 ; Issue:1 |
بيانات النشر: | BioMed Central |
سنة النشر: | 2024 |
المجموعة: | PubMed Central (PMC) |
مصطلحات موضوعية: | Hepatocellular carcinoma (HCC), Immunotherapy, Magnetic resonance imaging (MRI), Natural killer cell, Radiomics, Sorafenib |
الوصف: | Hepatocellular carcinoma (HCC) is a common liver malignancy with limited treatment options. Previous studies expressed the potential synergy of sorafenib and NK cell immunotherapy as a promising approach against HCC. MRI is commonly used to assess response of HCC to therapy. However, traditional MRI-based metrics for treatment efficacy are inadequate for capturing complex changes in the tumor microenvironment, especially with immunotherapy. In this study, we investigated potent MRI radiomics analysis to non-invasively assess early responses to combined sorafenib and NK cell therapy in a HCC rat model, aiming to predict multiple treatment outcomes and optimize HCC treatment evaluations. |
نوع الوثيقة: | article in journal/newspaper |
اللغة: | English |
العلاقة: | https://doi.org/10.1186/s12967-024-04873-wTest; https://pubmed.ncbi.nlm.nih.gov/38243292Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10797785Test/ |
DOI: | 10.1186/s12967-024-04873-w |
الإتاحة: | https://doi.org/10.1186/s12967-024-04873-wTest https://pubmed.ncbi.nlm.nih.gov/38243292Test https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10797785Test/ |
حقوق: | © 2024. The Author(s). |
رقم الانضمام: | edsbas.6AC482AE |
قاعدة البيانات: | BASE |
DOI: | 10.1186/s12967-024-04873-w |
---|